Savara Announces Participation in Upcoming Investor Healthcare Conferences
Wells Fargo Securities Healthcare Conference
September 3, 2025, 4:30pm ET/1:30pm PT
H.C. Wainwright Global Healthcare Conference
September 9, 2025, 1:00pm ET/10:00am PT
The live webcasts and subsequent replays will be available on the 鈥淓vents & Presentations鈥� section of the Company鈥檚 corporate website and will be archived for 90 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow庐 Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at and .
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.
View source version on businesswire.com:
Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
[email protected]
Source: Savara Inc.
